OPKO Health Invests in ChromaDex Corp.

OPKO Health, Inc.

and ChromaDex Corporation

announced today they have entered into a strategic alliance pursuant to which ChromaDex has licensed to OPKO all of its new product offerings and health care technologies for distribution and business development throughout all of Latin America. The initial products to be commercialized are BlūScience™ (www.bluscience.com), ChromaDex's recently launched line of dietary supplements, as well as ChromaDex's proprietary pterostilbene, branded as pTeroPure® (www.pteropure.com). OPKO recently made a $1,000,000 investment in ChromaDex as a participant in a private placement of 4,993,329 shares of ChromaDex common stock.